CO6180426A2 - Compuesto para el tratamiento de la hepatitis b - Google Patents
Compuesto para el tratamiento de la hepatitis bInfo
- Publication number
- CO6180426A2 CO6180426A2 CO09097263A CO09097263A CO6180426A2 CO 6180426 A2 CO6180426 A2 CO 6180426A2 CO 09097263 A CO09097263 A CO 09097263A CO 09097263 A CO09097263 A CO 09097263A CO 6180426 A2 CO6180426 A2 CO 6180426A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- alkylso2
- tetrahydrofuranyl
- Prior art date
Links
- 239000002131 composite material Substances 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- -1 hydroxy, benzyloxy Chemical group 0.000 abstract 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 2
- 229910003844 NSO2 Inorganic materials 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89488707P | 2007-03-14 | 2007-03-14 | |
| US98947407P | 2007-11-21 | 2007-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6180426A2 true CO6180426A2 (es) | 2010-07-19 |
Family
ID=39477552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09097263A CO6180426A2 (es) | 2007-03-14 | 2009-09-10 | Compuesto para el tratamiento de la hepatitis b |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7547690B2 (OSRAM) |
| EP (1) | EP2118109B1 (OSRAM) |
| JP (1) | JP5232178B2 (OSRAM) |
| KR (1) | KR20100015304A (OSRAM) |
| CN (1) | CN101657455B (OSRAM) |
| AR (1) | AR065772A1 (OSRAM) |
| AU (1) | AU2008226639B2 (OSRAM) |
| BR (1) | BRPI0808763A2 (OSRAM) |
| CA (1) | CA2681093A1 (OSRAM) |
| CL (1) | CL2008000751A1 (OSRAM) |
| CO (1) | CO6180426A2 (OSRAM) |
| EA (1) | EA016614B1 (OSRAM) |
| IL (1) | IL200905A0 (OSRAM) |
| MX (1) | MX2009009473A (OSRAM) |
| NZ (1) | NZ579342A (OSRAM) |
| PE (1) | PE20090648A1 (OSRAM) |
| TW (1) | TW200848058A (OSRAM) |
| WO (1) | WO2008112473A1 (OSRAM) |
| ZA (1) | ZA200906129B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688420A4 (en) * | 2003-11-19 | 2008-10-22 | Japan Tobacco Inc | 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| PL2209789T3 (pl) * | 2007-11-20 | 2012-04-30 | Bristol Myers Squibb Co | Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| AU2008339917B2 (en) | 2007-12-24 | 2013-02-07 | Tibotec Pharmaceuticals | Macrocyclic indoles as hepatitis C virus inhibitors |
| EP2280978B1 (en) * | 2008-03-27 | 2013-04-24 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| US8178523B2 (en) * | 2008-03-27 | 2012-05-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| BR112012013765A2 (pt) | 2009-12-07 | 2016-04-26 | Targacept Inc | 3,6-diazabiciclo[3.1.1] heptanos como ligantes de receptor nicotínico neuronal de acetilcolina |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| WO2014011863A1 (en) * | 2012-07-12 | 2014-01-16 | Targacept, Inc. | Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane |
| AU2013290402A1 (en) * | 2012-07-18 | 2015-03-05 | Bristol-Myers Squibb Holdings Ireland | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| JP2019510020A (ja) | 2016-03-15 | 2019-04-11 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 害虫を防除するための置換スルホニルアミド類 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN110028510A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法 |
| KR20220098170A (ko) | 2019-11-07 | 2022-07-11 | 바이엘 악티엔게젤샤프트 | 동물 해충 방제를 위한 치환된 술포닐 아미드 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005013922D1 (de) | 2004-02-24 | 2009-05-28 | Japan Tobacco Inc | Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7153848B2 (en) * | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2005298403A1 (en) | 2004-10-26 | 2006-05-04 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521442B2 (en) | 2006-05-25 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| CN101490054B (zh) | 2006-05-25 | 2012-05-16 | 百时美施贵宝公司 | 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
-
2008
- 2008-02-28 US US12/039,239 patent/US7547690B2/en active Active
- 2008-03-05 WO PCT/US2008/055893 patent/WO2008112473A1/en not_active Ceased
- 2008-03-05 KR KR1020097019018A patent/KR20100015304A/ko not_active Ceased
- 2008-03-05 AU AU2008226639A patent/AU2008226639B2/en not_active Ceased
- 2008-03-05 EA EA200901241A patent/EA016614B1/ru not_active IP Right Cessation
- 2008-03-05 BR BRPI0808763-6A patent/BRPI0808763A2/pt not_active IP Right Cessation
- 2008-03-05 JP JP2009553689A patent/JP5232178B2/ja not_active Expired - Fee Related
- 2008-03-05 CA CA002681093A patent/CA2681093A1/en not_active Abandoned
- 2008-03-05 MX MX2009009473A patent/MX2009009473A/es not_active Application Discontinuation
- 2008-03-05 CN CN200880008369XA patent/CN101657455B/zh not_active Expired - Fee Related
- 2008-03-05 NZ NZ579342A patent/NZ579342A/en not_active IP Right Cessation
- 2008-03-05 EP EP08743684.6A patent/EP2118109B1/en not_active Not-in-force
- 2008-03-13 TW TW097108906A patent/TW200848058A/zh unknown
- 2008-03-13 PE PE2008000473A patent/PE20090648A1/es not_active Application Discontinuation
- 2008-03-13 CL CL200800751A patent/CL2008000751A1/es unknown
- 2008-03-14 AR ARP080101085A patent/AR065772A1/es not_active Application Discontinuation
-
2009
- 2009-09-03 ZA ZA2009/06129A patent/ZA200906129B/en unknown
- 2009-09-10 CO CO09097263A patent/CO6180426A2/es active IP Right Grant
- 2009-09-13 IL IL200905A patent/IL200905A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200901241A1 (ru) | 2010-02-26 |
| AU2008226639B2 (en) | 2012-07-19 |
| KR20100015304A (ko) | 2010-02-12 |
| ZA200906129B (en) | 2010-11-24 |
| CN101657455B (zh) | 2013-02-06 |
| TW200848058A (en) | 2008-12-16 |
| EP2118109B1 (en) | 2014-11-26 |
| CN101657455A (zh) | 2010-02-24 |
| AR065772A1 (es) | 2009-07-01 |
| BRPI0808763A2 (pt) | 2014-09-16 |
| JP2010521476A (ja) | 2010-06-24 |
| WO2008112473A1 (en) | 2008-09-18 |
| EA016614B1 (ru) | 2012-06-29 |
| PE20090648A1 (es) | 2009-05-29 |
| US7547690B2 (en) | 2009-06-16 |
| IL200905A0 (en) | 2010-05-17 |
| JP5232178B2 (ja) | 2013-07-10 |
| EP2118109A1 (en) | 2009-11-18 |
| CL2008000751A1 (es) | 2008-07-25 |
| MX2009009473A (es) | 2009-09-15 |
| AU2008226639A1 (en) | 2008-09-18 |
| US20080227769A1 (en) | 2008-09-18 |
| CA2681093A1 (en) | 2008-09-18 |
| NZ579342A (en) | 2011-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6180426A2 (es) | Compuesto para el tratamiento de la hepatitis b | |
| AR061008A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo | |
| GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| MY135841A (en) | Novel benzodioxoles | |
| AR061053A1 (es) | Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo | |
| AR057810A1 (es) | Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica | |
| AR067528A1 (es) | Eteres heterociclicos sustituidos y su uso en trastornos del snc | |
| GEP20105053B (en) | Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| AR067897A1 (es) | Compuestos para el tratamiento de hepatitis c | |
| JP2010521483A5 (OSRAM) | ||
| TW200738242A (en) | Dihydropteridinones in the treatment of respiratory diseases | |
| IL177962A0 (en) | Compounds and methods for treating dyslipidemia | |
| MY144622A (en) | Agents for preventing and treating disorders involving modulation of the ryr receptors | |
| AR055165A1 (es) | Inhibidores ns5b de vhc de indolobenzacepina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la hepatitis c. | |
| AR035991A1 (es) | Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio | |
| MXPA06000716A (es) | Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1. | |
| GB0413087D0 (en) | Therapeutic compounds | |
| IL205697A0 (en) | 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof | |
| MX2012006962A (es) | Inhibidores de la esfingosina quinasa. | |
| PE20080144A1 (es) | Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa | |
| MX2007004183A (es) | Derivados de benzoimidazol utiles como agentes antiproliferacion. | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |